# A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

> **NCT04822350** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 596 (actual)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT04822350
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-13
- **Primary completion:** 2024-04-25
- **Final completion:** 2024-04-25
- **Target enrollment:** 596 (ACTUAL)
- **Last updated:** 2026-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04822350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04822350, "A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04822350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*